Insulin News
-
CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. Among these innovations is the development of coated microneedle preparation technology, which has shown promising results in delivering novel drugs to patients. CD formulation involves coated microneedles with specific drug compounds, allowing for controlled and sustained drug delivery. ...
-
CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...
-
Peer reviewed publications reporting the effectiveness of the Kurve intranasal insulin product
Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices. The blog - http://www.nasaldrugdeliveryblog.com - invites scientists, researchers ...
-
Modular Medical Announces Product Testing Update
Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product. The Company has continued to make progress on the testing required for its 510(k) submission ...
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
Modular Medical Provides Product Update
Modular Medical Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today provided an update on its insulin pump product. The Company has successfully completed the majority of the tests and documentation required for its 510(k) submission ...
-
Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
-
Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...
-
All patients in DiagnodE-B have received an additional (booster) injection of Diamyd
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. DIAGNODE-B (B for “booster”) assesses ...
-
Updated results from clinical trial with Diamyd presented today at diabetes conference
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated ...
-
Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
Promising topline results for intralymphatic Diamyd in patients with LADA
The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological ...
-
Diamyd Medical joins international consortium in Type 1 Diabetes
Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US non-profit organization the Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
New AMPK Pathways Offered to Support Metabolism Research
CD BioSciences, a US-based life science research product supplier and CRO, proudly offers AMPK Pathway to the life science community for researchers focusing on diabetes and metabolism study. These new signaling pathways and previously launched metabolic signaling pathways, such as insulin signaling pathway and mTOR pathway, will help support scientists in all aspects of cell death study. 5' ...
-
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific ...
-
First patient enrolled in Diamyd Medical`s Phase III trial Diagnode-3
The first patient has now received its first intralymphatic injection of Diamyd® in the precision medicine Phase III trial DIAGNODE-3. The trial will include approximately 330 patients aged 12 to 29 years newly diagnosed with Type 1 Diabetes who carry the genetically defined haplotype HLA DR3-DQ2. “The fact that the first patient is now enrolled in DIAGNODE-3 is a major milestone for ...
-
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B VX-880 generally well tolerated in all three patients dosed to date ...
-
CD BioSciences Releases Insulin Signaling Pathway for Researchers
CD BioSciences, a US-based life science research product supplier and CRO, recently introduces new insulin signaling pathways to the life science community for research uses. These new signaling pathways in combination with other metabolic signaling pathways, such as TOR pathway, and AMPK pathway can cover all aspects of cell death study for researchers. Metabolism describes the life-sustaining ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you